Investee iOx Therapeutics, in which SalvaRx's 94% owned subsidiary SalvaRx Ltd has a 61% interest, has recently bee granted further patents in the EU and US for liposomal formulation of its iNKT agonist therapy.
iOx, it said, is progressing its toxicology programme and manufacturing process to enable human testing to start soon. The company said iOx is also making progress on its second therapy, IMM65, to enable final formulation determination.
To fund this, iOx has issued
Investee Intensity Therapeutics has also been granted a US patent for its cell penetration enhances with anti-cancer therapies. A recent trial showed good safety in superficially-palpable tumours, and the trial has moved into deeper tumours such as those in the pancreas, liver, or colon.
SalvaRx Chief Executive Ian Walters said: "I am delighted with the portfolio of assets that we have put together as well as the teams behind these technologies. We have seen substantial progress across the portfolio and now are beginning to evolve into a clinical stage company with multiple assets expected in the clinic by the end of the year."
"The appetite for early stage immuno-oncology assets is still strong with recent record-breaking deals showing significant premiums. SalvaRx is well poised to deliver a series of novel first in class products which can augment the pipelines in big pharma."
Shares were up 0.7% on Thursday at
